Citations

Clear

2429 citation(s) found for "Shah, SS".

Top 5 Surgical Education Innovations for Low‐Resource Settings Over the Last 50 years
Choubey, Udit , Mbanje, Cassandra , Tak, Rajeeka Singh , Davies, Jessica , Rivera, Mariela , Rivera, Mariela , Mbanje, Cassandra Phillippa Tatenda

Mayo Clinic

World Journal of Surgery | June 9, 2026 | Volume: 50 | Issue: 8 | Pages: 2188-2194

10.1002/wjs.70443 | PMID 42261130 Get It

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Fathima, Saubia, Wong, Margaret Mei‐Kay, Gonzalez-Lugo, Jesus, Geyer, Susan M. , Alsugair, Ali, Langer, Kimberly J., Lasho, Terra L. , Finke, Christy, Choi, Jun, Abdul‐Hay, Maher, Ho, Gary , Litzow, M. R., Matin, Aasiya , Hefazi, M., Shah, Mithun V., Al-Kali, Aref, Begna, Kebede H. , Gangat, Naseema , Saliba, A., Kewan, Tariq, Bartoo, Gabriel, Kutzke, Jade, McCullough, Kristen, Sullivan, Megan, Reichard, Kaaren K., Olteanu, Horatiu , Kusne, Yael , Palmer, Jeanne, Punwani, Nathan , Riwes, Mary, Krakow, Elizabeth F., Langston, Amelia , Kourelis, Taxiarchis, Foran, James M. , Patnaik, Mrinal M., Beck, David B. , Mangaonkar, Abhishek A. , Krakow, Elizabeth F. , Riwes, Mary , Alsugair, Ali , Lasho, Terra L , Ho, Gary , Durani, Urshila , Hogan, William J , Gangat, Naseema , Saliba, Antoine N , Go, Ronald S , Warrington, Kenneth J , Olteanu, Horatiu , Murthy, Hemant S , Badar, Talha , Kusne, Yael N , Chhabra, Saurabh , Langston, Amelia , Foran, James M , Koster, Matthew J , Beck, David B , Alkhateeb, Hassan B , Fathima, Saubia , Gonzalez‐Lugo, Jesus D. , Geyer, Susan , Sirenko, Maria , Finke, Christy M. , Abdul‐Hay, Maher , Litzow, Mark R. , Durani, Urshila , Hefazi, Mehrdad , Hogan, William J. , Shah, Mithun V., Al‐Kali, Aref , Saliba, Antoine N. , Go, Ronald S. , Bartoo, Gabriel , Kutzke, Jade L. , McCullough, Kristen , Warrington, Kenneth J. , Sullivan, Megan M. , Reichard, Kaaren K. , Murthy, Hemant S. , Badar, Talha , Palmer, Jeanne , Chhabra, Saurabh , McGuirk, Joseph P. , Kourelis, Taxiarchis , Dingli, David , Koster, Matthew J. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Mangaonkar, Abhishek A.

Mayo Clinic

American Journal of Hematology | June 9, 2026 | Volume: 101 | Issue: 9 | Pages: 2166-2176

10.1002/ajh.70401 | PMID 42260942 Get It

ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA ( n = 35) or alloHSCT ( n = 31). Baseline characteristics such as genetics, co‐morbidities, and performance status were balanced between the groups, except older age in the HMA group. Median follow‐up from therapy initiation was 18 months (95% CI: 11–26), and 14 (21%) deaths were reported (alloHSCT n = 3; HMA n = 11). Among all evaluable patients within the alloHSCT cohort, all patients achieved molecular remission, and a substantial proportion of patients discontinued glucocorticoids (58%). In contrast, HMA therapy was associated with lower but meaningful rates of molecular remission (22%) and glucocorticoid discontinuation (6%). In a real‐world setting, HMA therapy was associated with a high discontinuation rate related to toxicity or lack of response. On multivariable analysis adjusted for age and Charlson Comorbidity Index, alloHSCT was associated with improved overall survival (HR = 0.20, 95% CI: 0.05–0.81; p = 0.024). This association remained consistent across multiple ancillary sensitivity analyses, including restriction to transplant‐eligible patients, patients aged ≤ 75 years, 1:1 matching, and propensity score‐based weighted analyses. Although limited by retrospective design, these findings suggest that alloHSCT remains an attractive and potentially curative strategy in selected patients with VEXAS. Prospective validation of these findings is warranted.
Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria
Li, Eric V. , Ahmed, Eman E., Ahmed, Mohamed E., Wang, Michael K., Diaz‐Cobo, Julian, O'Byrne, Jamie, Cheville, John C., Shah, Paras H., Frank, Igor, Tollefson, Matthew K., Boorjian, S., Sharma, Vidit, Khanna, Abhinav, Karnes, R Jeffrey, Ahmed, Mohamed E., Diaz-Cobo, Julian, Cheville, John C. , Frank, Igor, Tollefson, Matthew K. , Sharma, Vidit , Karnes, R. Jeffrey

Mayo Clinic

The Prostate | June 8, 2026 | Volume: 86 | Issue: 12 | Pages: 1251-1257

10.1002/pros.70206 | PMID 42257571 Get It

ABSTRACT Background While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era. Here we evaluate patient outcomes from a MRI‐screened AS‐eligible cohort of FIR GG2 PCa receiving radical prostatectomy (RP). Methods Patients with prostate MRI, NCCN FIR GG2 PCa (PSA < 10 ng/mL, ≤ cT2a, < 50% core positivity), and no prior treatments who underwent RP from 2015 to 2023 were included from a prospectively maintained prostatectomy registry. Primary outcomes were adverse pathologic features (APF) at RP (GG3‐5, ≥ pT3a, or pN1) and biochemical recurrence (BCR). Logistic regression and Cox regression identified factors associated with APF at RP and time to BCR, respectively. Results Of 522 patients, 110 (21%) had APF at RP and 45 (9%) developed BCR with median follow up 2.4 years (IQR 1.3–2.8). On multivariable logistic regression, % Gleason pattern 4 (%GP4, %GP4 > 25% OR 2.14, 95% CI 1.28–3.58, p = 0.004) was independently associated with APF. On multivariable Cox regression for time to BCR, PSAD (HR 1.06, 95% CI 1.04–1.09, p < 0.001) and positive surgical margins (HR 1.06, 95% CI 1.09–3.78, p = 0.03) were independently associated with BCR. PIRADS, % core positivity, and specimen involvement were associated with neither APF nor BCR. Conclusions % Gleason pattern 4 > 25% and PSAD are the primary factors associated with adverse outcomes and should be considered for patients with FIR GG2 PCa considering active surveillance. PIRADS and measures of biopsy cancer volume were not associated with APF or BCR. These results may inform patient selection for active surveillance among patients with FIR GG2 PCa.
Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women
Shah, Tiana, Tinker, Rory J., Weidner, Anne , Venton, Lindsay , Roberson, M., Lehmann, Brian D. , Couch, Fergus J., Reid, Sonya, Metcalfe, Kelly , Pal, Tuya, Tinker, Rory J. , Beasley, Heather K , Weidner, Anne , Venton, Lindsay , Metcalfe, Kelly A , Tinker, R J , Beasley, Heather K. , Hu, Chunling , Roberson, Mya L. , Lehmann, Brian David , Couch, Fergus J. , Pal, Tuya

Mayo Clinic

Cancer | June 8, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70402 | PMID 42252839 Get It

Abstract Background Black women are more likely to develop and die from early‐onset breast cancer. Hereditary breast cancer (HBC) is strongly associated with early age of onset. Accordingly, HBC characteristics in young Black women were evaluated. Methods Black women diagnosed with invasive breast cancer at age 50 years or younger between 2005 and 2018 were recruited through the state cancer registries in Florida and Tennessee. Participants were asked to complete a questionnaire, sign medical records releases, and donate a saliva sample for free genetic testing to identify HBC germline pathogenic or likely pathogenic variant (GPV). Women with sporadic versus hereditary breast cancer were compared, based on age distribution, clinical characteristics, and family cancer history. Results Among 686 participants with confirmed genetic testing, 15.3% had GPVs in breast and/or ovarian cancer predisposition genes, including BRCA1 (7.7%), BRCA2 (4.5%), PALB2 (0.9%), and ATM (0.7%), with 1.5% in other genes. Compared to the sporadic group, triple‐negative breast cancers were overrepresented among BRCA1 carriers (23.6% vs. 75.5%; p < .001), and family history of breast cancer was significantly more frequent among BRCA1 , BRCA2 , and PALB2 carriers (all p < .05). The majority of breast cancers occurred by age 40 years in BRCA1 carriers (52.8%), compared to other genes, where age was more evenly distributed. Conclusion Among unselected young Black women with breast cancer, our findings demonstrate that the highest frequency of HBC GPVs are in BRCA1 , BRCA2, and PALB2, with identification of distinct histopathologic and demographic characteristics across HBC genes, underscoring the critical need for genetic testing in all populations.
DHDDS-related juvenile parkinsonism is caused by impaired lipid metabolism, glycosylation, and mitochondrial dysfunction, which can be rescued by NAD⁺ treatment
Muffels, Irena , Kantautas, Kristin A , MacDonald, Georgia, Garapati, Kishore , Pasupuleti, Raghavendra R., Tinker, Rory J, Shah, Rameen , Thevandavakkam, Mathura A., Donnelly, Justin , Hrtska, Ron, Smith, Douglas, Klinken, Jan B. van , Pandey, Akhilesh, Perlstein, Ethan, Kantautas, Kristin A. , Tinker, Rory J. , Muffels, I J J , Garapati, Kishore , Tinker, R J , Vaz, F , Pandey, A , Perlstein, Ethan O , Kozicz, Tamas , Morava, Eva , Pasupuleti, Raghavendra Rao, Perlstein, Ethan , Kozicz, Tamás , Morava, Éva

Mayo Clinic

No container title available | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.28.26354198 | PMID 42282162 Get It

Abstract Background Mono-allelic Dehydrodolichyl Diphosphate Synthase ( DHDDS) variants are associated with juvenile Parkinsonism, developmental delay and seizures. Symptoms are progressive, and various mechanisms, such as defective glycosylation, lysosomal dysfunction and cholesterol accumulation have been hypothesized to underlie disease symptoms. There is no treatment for DHDDS-related disease. Methods Patient-derived cortical forebrain organoids were created to elucidate disease mechanisms and evaluate potential treatments. In these neuronal models, glycosylation, lipidomics, proteomics, cholesterol/ganglioside accumulation, mitochondrial function and electrophysiological activity were assessed. Finally, we investigated the effects of nicotinamide mononucleotide (NMN), identified through a yeast-based drug screen, in neuronal cell models and in six patients in an off-label, N-of-1, observational series. Results DHDDS-patient derived organoids showed visual signs of degeneration after four months of culturing. This was accompanied by significant cholesterol accumulation in astrocytes, decreased mitochondrial respiration and loss of deep-layer neurons. In addition, we identified glycosylation abnormalities, showing for the first time that glycosylation in human tissue is affected by monoallelic DHDDS variants. Proteomic analysis revealed altered protein expression of proteins involved in lipid metabolism, cytoskeletal organization and neuronal development. We found that oral Nicotinamide Mononucleotide supplementation led to significant improvement in mitochondrial respiration and electrophysiological parameters in organoids, concurring with clinical improvements in all of the treated patients, particularly regarding their ataxia and tremor. Conclusion Our findings reveal a progressive phenotype in DHDDS-patient-derived brain organoids, with mitochondrial dysfunction and astrocyte-specific metabolic alterations contributing to disease pathology. Notably, NMN treatment led to clinical improvements in patients with heterozygous DHDDS variants, highlighting its potential as a therapeutic strategy.
Interlobular Septal Thickening: A Pictorial Review
Walters, Courtney E. , Ruddy, Liane, Hasson, Evan, Jokerst, C, Stib, Matthew T. , Panse, Prasad M., Rojas, Carlos, Shah, Amar S, Shah, Amar , Gotway, Michael B.

Mayo Clinic

Journal of Computer Assisted Tomography | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/rct.0000000000001891 | PMID 42240111 Get It

Interlobular septal thickening (ILST) is a feature on chest computed tomography (CT) that is characterized by abnormal widening of the interlobular septa, which are thin connective tissues that separate secondary pulmonary lobules within the lung parenchyma. They contain pulmonary venules and lymphatic vessels. On CT, these septa are normally not visible in healthy patients. However, various pulmonary pathologic conditions can lead to ILST. If present, ILST can be categorized into 3 different patterns based on its morphologic appearance: smooth, nodular, and irregular/fibrotic. Each pattern occurs from different disease processes with little overlap. In this pictorial essay, we review common and rare etiologies for each type of ILST. For each disease, we discuss relevant pathophysiology, epidemiology, risk factors, symptoms, physical exam findings, labs, and management. Subsequently, we present the ILST features along with the distribution (eg, unilateral, bilateral, central, peripheral) and ancillary imaging findings that can support the diagnosis. Finally, characteristic and high-resolution figures are presented.
Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients With Severe Alcohol-Associated Hepatitis
Ventura-Cots, Meritxell, Clemente, Ana, Alvarado-Tapias, Edilmar, Ravi, Sujan, Cuyàs, Berta , Tanguy, M, Poca, Maria, Jäger, Marion , Arteel, Gavin E. , Villagrasa, Ares, Aguilar-Amorós, Anna, Argemí, Josepmaria , Abraldes, Juan G., Bosques, Francisco, Brown, R, Garcia-Taso, Guadalupe, Genesca, Juan, Schanbl, Bernd, Mathurin, P., Louvet, Alexander, Lucey, Michael R., Shawcross, Debbie L., Verna, Elisabeth, Dasarathy, S, Tu, Wanzhu, Kamath, Patrick S, Chalasani, Naga P, McClain, Craig J, Szabo, Gyongyi, Tang, Qing, Barton, Bruce, Nagy, Laura E. , Shah, Vijay H, Sanyal, Arun J, Singal, Ashwani K, Soriano, Germà, Rautou, Pierre Emmanuel, Shawcross, Debbie L. , Ventura Cots, Meritxell , Bataller, Ramon A , Shawcross, Debbie Lindsay , Cuyas, Berta , Ventura‐Cots, Meritxell , Alvarado‐Tápias, Edilmar , Ravi, Sujan, Tanguy, Marion , Poca, María , Fernández‐Carrillo, Carlos , Villagrasa, Ares , Abraldeṣ, Juan G. , Genescà, Joan , Mathurin, Philippe , Lucey, Michael R., Gawrieh, Samer , Tu, Wanzhu , Kamath, Patrick S. , Chalasani, Naga , McClain, Craig J. , Tang, Qing , Shah, Vijay H. , Sanyal, Arun J. , Mitchell, Mack , Singal, Ashwani K. , Rautou, Pierre-Emmanuel

Mayo Clinic

Clinical and Translational Gastroenterology | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ctg.0000000000001053 | PMID 42235929 Get It

INTRODUCTION: Alcohol-associated hepatitis (AH) is a severe condition with high short-term mortality. Identifying key predictors of poor outcomes is critical for guiding therapeutic strategies. Mean arterial pressure (MAP), a key determinant of tissue perfusion and systemic hemodynamics, may play a pivotal role in prognosis. METHODS: We analyzed a multicenter, prospective cohort of 323 patients hospitalized with AH, with validation in an independent cohort of 290 patients. Survival was evaluated using Kaplan-Meier curves and compared with the log-rank (Mantel-Cox) test. Cox proportional hazards models were used to estimate hazard ratios for mortality, adjusted for Model for end stage liver disease score. Mechanistic insights were explored through assessment of cardiovascular biomarkers. RESULTS: A baseline MAP <80 mm Hg was associated with significantly higher mortality at both 28 days (27.3% vs 8.0%) and 90 days (40.3% vs 15.6%; P < 0.001 for both). This association persisted after adjusting for Model for end stage liver disease score, age, and baseline hepatic encephalopathy. The incidence of infections during follow-up was similar across MAP groups (27.6% vs 22.8%), but acute kidney injury occurred more frequently in the MAP <80 mm Hg group (62% vs 38%, P < 0.001). In the validation cohort, patients with MAP <80 mm Hg also demonstrated significantly lower 28-day transplant-free survival. Although B-type natriuretic peptide and plasma renin levels were altered in patients with AH, they did not correlate with MAP values. DISCUSSION: A baseline MAP <80 mm Hg is an independent predictor of short-term and mid-term mortality in patients with AH. Strategies aimed at restoring hemodynamic stability may improve outcomes in this high-risk population.
Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial
Goel, Kashish , Lindman, Brian R. , Schwartz, Allan, Cohen, DE, Giustino, Gennaro, Oldemeyer, J. Bradley , Strote, Justin, Babaliaros, Vasilis, Devireddy, Chandan , Fischbein, Michael P. , Fearon, W F, Daniels, David, Spies, Christian, Shah, Pinak , Dahle, Thom, Apostolou, Dimitrios , Makkar, R, Davidson, Charles J. , Sheth, Tej, Sorajja, Paul , DeVries, James T. , Southard, J.H., Depta, Jeremiah P. , Pop, Andrei, Rinaldi, Michael J., Badr, Salem , Russo, Mark J., Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Cohen, David J. , Schwartz, Allan , Cohen, David Jonathan , Babaliaros, Vasilis , Devireddy, Chandan M , Fearon, William F , Chhatriwalla, Adnan K , Suradi, Hussam , Shah, Pinak , Szerlip, Molly , Dahle, Thom , Apostolou, Dimitrios , Makkar, Raj , Davidson, Charles J. , Sorajja, Paul , DeVries, James T , Southard, Jeffrey , Depta, Jeremiah P , Badr, Salem , Guerrero, Mayra E , McCabe, James M , Pibarot, Phillippe , Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Lindman, Brian R , Giustino, Gennaro , Babaliaros, Vasilis , Fearon, William F. , Makkar, Raj , Sheth, Tej , Rinaldi, Michael , Williams, Mathew , Russo, Mark J., Guerrero, Mayra

Mayo Clinic

Circulation: Cardiovascular Interventions | June 3, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.016370 | PMID 42233211 Get It

BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus CS strategy by age is unknown. METHODS: The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age. RESULTS: No interaction was detected between age and the treatment effect of early TAVR versus CS for the composites or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65–69 years, absolute risk reduction, 13%; P =0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; P =0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75–79 years, 5.9%; 70–74 years, 5.1%; 65–69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; P =0.73). Approximately one-third of younger patients (65–69 years) in the CS arm presented with acute valve syndrome at the time of conversion, the frequency of which tended to increase with age ( P =0.06). CONCLUSIONS: In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03042104.